Geodon for the Treatment of Refractory Social Anxiety Disorder

NCT00215150

Last updated date
Study Location
Duke University Medical Center
Durham, North Carolina, 27701, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Social Anxiety Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- adults 18-65 years of age

- primary diagnosis of SAD, using Diagnostic Standard Manual(DSM-IV) criteria

- minimum Clinical Global Impression of Severity (CGI-S) score of 4 at baseline

- minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline

- written informed consent

- negative serum pregnancy test for women of childbearing potential

- normal EKG

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic
disorder, mental retardation or other pervasive developmental disorder, or cognitive
disorder due to a general medical condition


- any current primary anxiety disorder other than SAD


- current primary depression


- history of substance abuse or dependence within the last 3 months


- suicide risk or serious suicide attempt within the last year


- clinically significant medical condition or laboratory or EKG abnormality


- women of childbearing potential who are unwilling to practice an acceptable method of
contraception


- patients needing concurrent use of psychotropic medications


- history of hypersensitivity to sertraline or ziprasidone


- recent (less than 2 months) initiation of psychotherapy for SAD


- history of failure to respond to augmentation with an adequate trial of an atypical
antipsychotic


- patients who are currently taking any of the following medications: Erythromycin,
Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and
Levitra

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Social Anxiety DisorderGeodon for the Treatment of Refractory Social Anxiety Disorder
NCT00215150
  1. Durham, North Carolina
  2. Durham, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Social Anxiety Disorder12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
NCT01316302
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Social Anxiety DisorderStudy Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
NCT00238719
ALL GENDERS
8 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Geodon for the Treatment of Refractory Social Anxiety Disorder
Official Title  ICMJE Ziprasidone for the Treatment of Refractory Social Anxiety Disorder
Brief Summary The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
Detailed Description This is a two-phase study consisting of 8 weeks of open label treatment with sertraline (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation with ziprasidone.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Social Anxiety Disorder
Intervention  ICMJE
  • Drug: Ziprasidone
    Sertraline augmentation with ziprasidone
    Other Name: Geodon
  • Drug: Sertraline
    Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
    Other Name: Zoloft
Study Arms  ICMJE
  • Open Label Treatment
    8 weeks of open label treatment with sertraline
    Intervention: Drug: Sertraline
  • Randomization Ziprasidone
    8 weeks of treatment with sertraline augmented with ziprasidone
    Interventions:
    • Drug: Ziprasidone
    • Drug: Sertraline
  • Randomization Placebo
    8 weeks of treatment with sertraline augmented by placebo
    Intervention: Drug: Sertraline
Publications * Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, Wilson W. The Brief Social Phobia Scale. J Clin Psychiatry. 1991 Nov;52 Suppl:48-51.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 16, 2013)
51
Original Enrollment  ICMJE
 (submitted: September 20, 2005)
40
Actual Study Completion Date  ICMJE July 2009
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • adults 18-65 years of age
  • primary diagnosis of SAD, using Diagnostic Standard Manual(DSM-IV) criteria
  • minimum Clinical Global Impression of Severity (CGI-S) score of 4 at baseline
  • minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline
  • written informed consent
  • negative serum pregnancy test for women of childbearing potential
  • normal EKG

Exclusion Criteria:

  • current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition
  • any current primary anxiety disorder other than SAD
  • current primary depression
  • history of substance abuse or dependence within the last 3 months
  • suicide risk or serious suicide attempt within the last year
  • clinically significant medical condition or laboratory or EKG abnormality
  • women of childbearing potential who are unwilling to practice an acceptable method of contraception
  • patients needing concurrent use of psychotropic medications
  • history of hypersensitivity to sertraline or ziprasidone
  • recent (less than 2 months) initiation of psychotherapy for SAD
  • history of failure to respond to augmentation with an adequate trial of an atypical antipsychotic
  • patients who are currently taking any of the following medications: Erythromycin, Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and Levitra
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00215150
Other Study ID Numbers  ICMJE Pro00012882
6479 ( Other Identifier: Duke legacy protocol number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Duke University
Study Sponsor  ICMJE Duke University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Wei Zhang, M.D.Duke University
PRS Account Duke University
Verification Date April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP